Dr. Sabine Straus has been with the Medicines Evaluation Board (MEB) in The Netherlands since 1997, where she started as an assessor Pharmacovigilance. Prior to working at MEB she held different positions in the pharmaceutical industry for 12 years, her last job was Medical Director at Searle Monsanto in The Netherlands. In the period 2001 - 2004 she combined her work at the MEB with a research position at the Erasmus Medical Center in Rotterdam on the topic "drugs, Qtc prolongation and sudden cardiac death". In addition she started her training as clinical epidemiologist at the same university and completed her Master of Science in Clinical Epidemiology in 2002. Her research resulted in a PhD degree in 2005.
From December 2005 until July 2012 she was Head of the Department of Pharmacovigilence. As of July 2012 she is a staff member at the MEB and the Dutch representative in the Pharmacovigilance Risk Assessment Committee (PRAC). In addition to her work at the MEB she holds a position as associate professor at the Erasmus Medical Center, department of Medical Informatics in Rotterdam. Her main research focus is on additional risk minimisation, pregnancy prevention programs, signal detection and signal management.